$1.01 Billion is the total value of GREAT POINT PARTNERS LLC's 41 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 250.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PTCT | Buy | PTC THERAPEUTICS INC | $68,289,000 | +62.4% | 1,814,260 | +48.1% | 6.76% | +27.2% |
ZGNX | Buy | ZOGENIX INC | $65,987,000 | +81.0% | 1,199,545 | +20.0% | 6.53% | +41.7% |
XLRN | Buy | ACCELERON PHARMA INC | $50,301,000 | +11.4% | 1,080,113 | +4.2% | 4.98% | -12.7% |
ASND | New | ASCENDIS PHARMA ASsponsored adr | $48,846,000 | – | 415,000 | +100.0% | 4.84% | – |
ICPT | Buy | INTERCEPT PHARMACEUTICALS INCput | $44,744,000 | +122.0% | 400,000 | +100.0% | 4.43% | +73.8% |
UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $44,581,000 | +16.7% | 379,832 | +8.3% | 4.41% | -8.6% |
GNFT | New | GENFIT SAads | $29,528,000 | – | 1,230,314 | +100.0% | 2.92% | – |
EPZM | New | EPIZYME INC | $26,935,000 | – | 2,173,913 | +100.0% | 2.67% | – |
ASND | New | ASCENDIS PHARMA ASput | $23,540,000 | – | 200,000 | +100.0% | 2.33% | – |
DERM | New | DERMIRA INC | $20,325,000 | – | 1,500,000 | +100.0% | 2.01% | – |
FGEN | New | FIBROGEN INCput | $10,870,000 | – | 200,000 | +100.0% | 1.08% | – |
CTMX | New | CYTOMX THERAPEUTICS INC | $10,310,000 | – | 959,077 | +100.0% | 1.02% | – |
BHVN | New | BIOHAVEN PHARMACTL HLDG COput | $10,294,000 | – | 200,000 | +100.0% | 1.02% | – |
DERM | New | DERMIRA INCput | $7,524,000 | – | 555,300 | +100.0% | 0.74% | – |
ARRY | New | ARRAY BIOPHARMA INCcall | $4,876,000 | – | 200,000 | +100.0% | 0.48% | – |
MNTA | New | MOMENTA PHARMACEUTICALS INC | $4,498,000 | – | 309,564 | +100.0% | 0.44% | – |
PTI | Buy | PROTEOSTASIS THERAPEUTICS INC | $4,410,000 | -55.3% | 3,500,000 | +14.9% | 0.44% | -65.0% |
SLDB | New | SOLID BIOSCIENCES INCcall | $1,840,000 | – | 200,000 | +100.0% | 0.18% | – |
NVAX | New | NOVAVAX INCput | $1,102,000 | – | 2,000,000 | +100.0% | 0.11% | – |
AKBA | New | AKEBIA THERAPEUTICS INC | $1,077,000 | – | 131,531 | +100.0% | 0.11% | – |
ZYME | New | ZYMEWORKS INC | $236,000 | – | 14,610 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-04-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.